(Q38105625)

English

Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy

scientific article published on 14 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

World Health Organization

0 references

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Erlend B. Smeland

10

object named as

Erlend Bremertun Smeland

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

7

object named as

Harald Holte

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Eric Hjalmarsson

6

object named as

Eric Hjalmarsson

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Birger Christensson

4

object named as

Birger Christensson

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Björn Engelbrekt Wahlin

1

object named as

Björn Engelbrekt Wahlin

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Christer Sundström

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Birgitta Sander

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Åsa Jeppsson-Ahlberg

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Bjørn Østenstad

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Peter D Brown

9

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Eva Kimby

11

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

14 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

288-295

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Follicular lymphoma in the United States: first report of the national LymphoCare study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Follicular lymphomas.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

The future of anti-CD20 monoclonal antibodies: are we making progress?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Interindividual variability of response to rituximab: from biological origins to individualized therapies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

First-line treatment of follicular lymphoma: a patient-oriented algorithm

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.802778

21 January 2018

Identifiers

10.3109/10428194.2013.802778

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38105625&oldid=2161076910"